The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001181392p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
2/09/2026
Date registered
Help: Date registered
23/09/2026
Date last updated
Help: Date last updated
23/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
23/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Can Immersion Therapy reduce pain and improve daily activities for people with Long-Term Low Back Pain?
Scientific title
Assessing the effects and feasibility of immersion Therapy on pain and everyday function in individuals with chronic non-specific low back pain
Additional trial identifiers [1] 318011 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
chronic non-specific low back pain 343042 0
Condition category
Condition code
Musculoskeletal 339156 339156 0 0
Other muscular and skeletal disorders
Physical Medicine / Rehabilitation 339571 339571 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Immersion Therapy (IT), a pool-based underwater experience, is designed for individuals with injuries or disabilities. It utilizes Self-Contained Underwater Breathing Apparatus (SCUBA) equipment and has been developed by the organization Determined2 in 2015 and ensures a comprehensive model for medical screening and safe operating procedures. Conducted in a swimming pool with a depth of 2-5 meters, IT sessions involve standard SCUBA equipment, such as a regulator or full-face mask connected to a 10–12-liter air tank, a buoyancy control device, and additional equipment like flippers, lead weights, foam floats, and other devices to facilitate fully submerged therapeutic exercise, delivered by IT specialists (ITS) who are university qualified health professionals (Accredited Exercise Physiologists or Registered Physiotherapists) who have completed specialized training in the IT. To ensure clinical safety and compliance, all specialists maintain current professional registration, appropriate insurances and registrations and undergo annual recertification. IT specialists provide support based on individual needs, ranging from physical assistance for completing tasks to mere supervision for independent participants.
The intervention sessions will be conducted in person at the Adelaide Aquatic Centre, located on Jeffcott Road, North Adelaide, SA 5006, Australia.
Participants will attend two 45-minute IT sessions per week over four weeks, for a total of eight sessions with each session delivered individually to one participant at a time.
Examples of exercises that participants might will be asked to perform during IT sessions include underwater walking or running, with or without additional weights, squats and lunges, step-ups, resisted lower-limb movements. Exercise selection and progression will be individualised according to each participant’s abilities, symptoms, and therapeutic goals.
A 2-week booster intervention phase (B') will be initiated if outcomes return to or exceed baseline (pre-intervention) levels for two consecutive weeks. This phase length will not be randomised.
Adherence will be monitored through attendance records and participants will be given a reminder of session by the ITS via phone or email two days before each session.
Intervention code [1] 334953 0
Treatment: Other
Intervention code [2] 334954 0
Rehabilitation
Description of the comparator or control
Eligible participants will be randomised into one of two baseline lengths (2 or 3 weeks), delivered non-concurrently.

During the baseline phase (A), participants will continue their usual daily activities without receiving IT as part of the study. They will complete the scheduled outcome assessments at predetermined time points, including measures of pain intensity and pressure pain threshold, the Oswestry Disability Index (ODI) to assess disability related to low back pain, and weekly assessments of physical activity using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). Participants will also wear an accelerometer for the predetermined 7-day assessment period to objectively assess physical activity. Any treatments or medication use during the baseline phase will also be recorded.

After completion of baseline monitoring (A), participants will begin their Immersion Therapy sessions (intervention phase, B).

A second baseline/withdrawal phase (A') of 3 or 2 weeks, respectively, will then follow, such that the combined duration of A and A' is 5 weeks. During A', IT will be withdrawn and the same outcome measures will continue to be monitored. Each participant will serve as their own control as during the withdrawal phase, changes in the measures will be monitored to assess whether they return towards baseline A.
Control group
Active

Outcomes
Primary outcome [1] 346428 0
Pain
Timepoint [1] 346428 0
Pressure pain threshold will be assessed using a handheld algometer at the participant’s primary painful lumbar region, identified by the researcher during the baseline assessment based on the participant’s reported location of their usual low back pain. The anatomical site will be recorded for each participant and kept consistent across subsequent assessments to standardise repeated measurements. Algometer measurements will be completed in person at Adelaide University (P2-42A), City East Campus, or at the participant’s home, according to their preference. Each assessment will take approximately 1 minute. Measurements will be obtained at either four or six baseline time points over a 2–3-week period, according to the participant’s randomised baseline allocation. During the intervention phase, pressure pain threshold will be assessed before each IT session. Following the final IT session, measurements will be obtained at either four or six follow-up time points over the subsequent 2–3 weeks, according to the corresponding assessment schedule. If the booster intervention phase (B') is initiated, pressure pain threshold will also be assessed before each IT session during the two-week booster period.
Primary outcome [2] 346429 0
Physical Function
Timepoint [2] 346429 0
Accelerometer data will be collected on a weekly basis throughout 11 weeks of study period, with participants wearing the device continuously over each 7-day period.
Primary outcome [3] 346430 0
Activities of daily livings
Timepoint [3] 346430 0
The ODI will be completed twice weekly during the baseline phase (4 or 6 assessments over 2–3 weeks, depending on participant's randomisation allocation) and repeated twice weekly during the follow-up phase (4 or 6 assessments over the subsequent 2–3 weeks, following the participants' last IT session). If Booster Intervention Phase (B') will be initiated, consisting of two weeks of additional IT sessions ODI will be assessed before each IT session.
Secondary outcome [1] 465800 0
Physical Activity
Timepoint [1] 465800 0
IPAQ will be administered once per week throughout 11 weeks of study period. This will be collected through the Qualtrics or in person at Adelaide University (P2-42A), city east campus or at their homes depending on participant preference.
Secondary outcome [2] 465826 0
Patient Experiences
Timepoint [2] 465826 0
Interviews will be conducted one week after completion of the 11-week study period.
Secondary outcome [3] 467834 0
Pain intensity (Primary Outcome)
Timepoint [3] 467834 0
BPI will be administered twice weekly throughout the baseline phases and before each IT session and will take approximately 2 minutes to complete each time. The measure will be collected through the Qualtrics or in person at Adelaide University (P2-42A), city east campus or at their homes depending on participant preference.
Secondary outcome [4] 467857 0
Feasibility of intervention
Timepoint [4] 467857 0
Attendance will be recorded by the IT specialist delivering each session using the participant’s session record. A threshold of 80% of scheduled sessions attended by participants will indicate that the intervention is feasible.
Secondary outcome [5] 467863 0
Feasibility of outcomes
Timepoint [5] 467863 0
Completion of outcome measures will be recorded using the study assessment records. Obtaining 50% of scheduled outcome measures across the eleven weeks will demonstrate the feasibility of the outcome measures.
Secondary outcome [6] 467866 0
Acceptability of the intervention
Timepoint [6] 467866 0
To evaluate acceptability of the intervention participants will be asked to rate acceptance on a numerical scale ranging from 1 to 5 at the end of week 11. A median score of 4/5 will be considered acceptable, while a score of 2/5 will be deemed feasible.
Secondary outcome [7] 467868 0
Perceived burden of the outcome measures
Timepoint [7] 467868 0
To evaluate perceived burden of the completion of the outcome measures, participants will be asked to provide a rating at the end of Week 11 using a numerical rating scale ranging from 1 to 5, where 1 indicates very low perceived burden and 5 indicates very high perceived burden. A median score of =2/5 will indicate low perceived burden.

Eligibility
Key inclusion criteria
Eligible participants will be adults aged 18 years or older with chronic non-specific low back pain lasting more than six months. Participants must be proficient in English, have access to mobile data for study communication and data collection, and be able to attend the Immersion Therapy facility for 8 sessions.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they do not pass the IT medical screening or are unable to complete the 11-week study protocol and scheduled assessments.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will not be used in this study. Participants will be allocated to one of the two baseline assessment patterns using a random number generator within predefined pairs, with one participant in each pair assigned to each pattern. As the allocation concerned only the timing and frequency of baseline assessments rather than assignment to an intervention or control group.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will be conducted in pairs using a computer-based random number generator.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Participants will undergo an 11-week Single Case Experimental design (SCED) consisting of an initial baseline phase (A) of either 2 or 3 weeks, followed by a 4-week intervention phase (B) comprising eight IT sessions. Each participant will serve as their own control, with outcomes during the intervention phase compared with those measured during the baseline phase. A second baseline/withdrawal phase (A') of 3 or 2 weeks, respectively, will then follow, such that the combined duration of A and A' is 5 weeks. A 2-week booster intervention phase (B') will be initiated if outcomes return to or exceed baseline (A) levels for two consecutive weeks.
Lastly, at the end of the program, participants will be asked to share their thoughts, feelings, and experiences about IT sessions. This will help us understand how the IT has affected pain management journey and identify any barriers participants may have faced. These semi-structured interviews will be conducted in person or via Zoom.
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
A sample of 8 participants is sufficient to demonstrate replicable effects across cases, provide detailed data on feasibility, acceptability, and preliminary outcomes. This size allows rich, high-frequency data collection while laying the groundwork for larger future trials. The proposed sample size of eight participants is appropriate for the study design, which uses a Single-Case Experimental Design (SCED) with a multiple-baseline approach. SCED methodology is well established in rehabilitation and clinical research for evaluating preliminary intervention effects, feasibility, and individual response patterns within small samples. In multiple-baseline SCED studies, each participant serves as their own control, allowing repeated within-subject measurements across baseline and intervention phases to strengthen internal validity without requiring large participant numbers.
As this project is exploratory and focused on feasibility, acceptability, safety, and preliminary clinical outcomes, a formal sample size calculation was not undertaken. Instead, the sample size was informed by methodological guidance for SCED research, practical feasibility considerations, and repeated assessments.
The study is not intended to provide definitive evidence of effectiveness or be statistically powered for group-level comparisons. Rather, it aims to generate preliminary evidence regarding intervention implementation, participant response trends, outcome measure suitability, and protocol feasibility to inform future larger-scale research.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 322636 0
Commercial sector/Industry
Name [1] 322636 0
Determined 2
Country [1] 322636 0
Australia
Primary sponsor type
University
Name
Adelaide University
Address
Country
Australia
Secondary sponsor category [1] 325558 0
None
Name [1] 325558 0
Address [1] 325558 0
Country [1] 325558 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321036 0
Adelaide University HREC 2
Ethics committee address [1] 321036 0
Ethics committee country [1] 321036 0
Australia
Date submitted for ethics approval [1] 321036 0
15/10/2025
Approval date [1] 321036 0
Ethics approval number [1] 321036 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152450 0
A/Prof Kade Davison
Address 152450 0
Adelaide University, GPO Box 2471, Adelaide, South Australia 5001
Country 152450 0
Australia
Phone 152450 0
+61883021152
Fax 152450 0
Email 152450 0
Contact person for public queries
Name 152451 0
Kade Davison
Address 152451 0
Adelaide University, GPO Box 2471, Adelaide, South Australia 5001
Country 152451 0
Australia
Phone 152451 0
+61883021152
Fax 152451 0
Email 152451 0
Contact person for scientific queries
Name 152452 0
Kade Davison
Address 152452 0
Adelaide University, GPO Box 2471, Adelaide, South Australia 5001
Country 152452 0
Australia
Phone 152452 0
+61883021152
Fax 152452 0
Email 152452 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Teaching research methods or developing new statistical techniques
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 15 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Requests to individual participant data can be made to Primary Investigator Kade Davison or PhD candidate via Email: [email protected].
[email protected]


Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Statistical analysis planNo Data Analysis Plan.docx

Documents added automatically
No additional documents have been identified.